Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
about
Progress of molecular targeted therapies for prostate cancersBiologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.Bone-targeting agents in prostate cancer.The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progressionGrowth factors and their receptors in prostate cancer.A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancerTyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinasesPhase I study of olaratumab in Japanese patients with advanced solid tumors.Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.Chemotherapy of prostate cancer: present and future.Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancerPhase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerA novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthInsulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG statusDisruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg ratEvidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate CancerThe inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells.Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysisPromising tumor-associated antigens for future prostate cancer therapy.Docetaxel-based combination therapy for castration-resistant prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasisSmall-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.Biochemical Changes in the Niche Following Tumor Cell Invasion.Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.Phase II study of sunitinib in men with advanced prostate cancer.
P2860
Q26823014-13112107-845C-40CE-8195-39B10C1E36B7Q33625089-EB3A120D-A7B9-4CB5-B539-86D1C15886B3Q33864723-E77D2321-AE9F-4F82-B159-0DFD4FE80FDAQ33874232-ABB0B7C7-DBF4-409A-B940-C633948E6F14Q34109373-D15679D0-0C49-403C-943B-1B555A4F64BBQ34140712-57745D92-790E-4917-BB74-25D03DFCEA78Q34302881-6AEA6F69-50A1-4C16-9ED8-811B268D85D5Q34320113-7092713E-92C4-4273-B830-21DBB6C38053Q34394070-C82912E0-0B2F-46D4-BC3B-10BCCF13215EQ34539272-1807515A-8973-4284-A35F-528766AEE0D4Q34683885-4DED6A2C-91EC-4147-89D4-BF09C698D118Q34743655-99C2FE6C-E0A4-4FC2-84C3-08D17D389726Q35051852-F427FD11-9623-4760-A5CC-45ADCCF91276Q35112059-E585497B-AB65-40F0-9516-8D0E30EF7DE9Q35131057-B3D5240A-5FC6-4BD9-BF5C-6DC795806DE8Q35555303-349AB708-9315-4DF0-BDFA-CA7369DA1289Q35679456-09D0D522-F67A-4814-B9D4-F81DEC6FEBE1Q35952035-D57BE014-2B93-451F-8728-53D8C1319E69Q36166836-46D47AAF-0BE1-40FC-98A0-D354073C5FC6Q36352562-1D3A09B6-F532-427F-87E7-A55741EED18CQ36381818-339E50FC-BE3C-477D-8325-B2E47379E740Q36509813-A507E675-173C-42EE-BB38-DAC1524458DCQ36699939-3FCA8D34-BC7D-484C-938A-32E35026ADCDQ37037837-E7076832-4DC3-470B-A5D9-933E74442E42Q37203589-8F3D2734-6243-4C77-A51F-A4A2153192AAQ37523602-8F436B59-4001-44BA-A3EE-F6C511E4D1FDQ37721016-8A77278A-39F0-4AC6-926E-CD82F98152BAQ37827186-A135438E-504D-4B52-BF96-4925B59B2C29Q37924342-4B84AE65-CE0F-494A-A1F2-123E3E6841E2Q37968256-D015455F-E4DB-4F76-A852-ED0C321D9B76Q38094296-C9891B26-4433-4567-8D09-D828CD526663Q38185175-C1918C39-CADB-4943-BED8-4A9DEB286115Q38262816-E2305BFD-52CE-4F66-9C22-609E05B15BB9Q38298477-9EAE836B-F457-4384-AE08-7FC03708D3E3Q38974204-5F30CA1B-0B77-4B6D-A8E3-79C9F377CE85Q39041143-00F871C5-1FB2-41B7-A8ED-76DCE31A08F2Q39644572-71F624BD-A46A-4AC9-8B93-AAE68E7ABA71Q39711107-B20FB7E8-0942-43CE-AF65-599620A072F0Q39881796-087DB85E-BF0B-42D8-B0D7-2429E0E3C6EAQ39983597-C8CE0BCE-A6E4-4300-9DE6-302473B6B7DA
P2860
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Tyrosine kinases expressed in ...... in-like growth factor receptor
@ast
Tyrosine kinases expressed in ...... in-like growth factor receptor
@en
type
label
Tyrosine kinases expressed in ...... in-like growth factor receptor
@ast
Tyrosine kinases expressed in ...... in-like growth factor receptor
@en
prefLabel
Tyrosine kinases expressed in ...... in-like growth factor receptor
@ast
Tyrosine kinases expressed in ...... in-like growth factor receptor
@en
P2093
P2860
P1476
Tyrosine kinases expressed in ...... in-like growth factor receptor
@en
P2093
D Morganstern
G J Bubley
I Mosberger
P2860
P304
P356
10.1016/S0002-9440(10)65229-7
P407
P577
1999-10-01T00:00:00Z